Literature DB >> 22727277

Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models.

Christopher M Acker1, Stefanie K Forest, Ray Zinkowski, Peter Davies, Cristina d'Abramo.   

Abstract

Transgenic mouse models have been an invaluable resource in elucidating the complex roles of β-amyloid and tau in Alzheimer's disease. Although many laboratories rely on qualitative or semiquantitative techniques when investigating tau pathology, we have developed 4 Low-Tau, Sandwich enzyme-linked immunosorbent assays (ELISAs) that quantitatively assess different epitopes of tau relevant to Alzheimer's disease: total tau, pSer-202, pThr-231, and pSer-396/404. In this study, after comparing our assays with commercially available ELISAs, we demonstrate our assay's high specificity and quantitative capabilities using brain homogenates from tau transgenic mice, htau, JNPL3, and tau knockout. All 4 ELISAs show excellent specificity for mouse and human tau, with no reactivity to tau knockout animals. An age-dependent increase of serum tau in both tau transgenic models was also seen. Taken together, these assays are valuable methods to quantify tau and phospho-tau levels in transgenic animals, by examining tau levels in brain and measuring tau as a potential serum biomarker.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727277      PMCID: PMC3474864          DOI: 10.1016/j.neurobiolaging.2012.05.010

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  44 in total

1.  A genomic sequence analysis of the mouse and human microtubule-associated protein tau.

Authors:  P Poorkaj; A Kas; I D'Souza; Y Zhou; Q Pham; M Stone; M V Olson; G D Schellenberg
Journal:  Mamm Genome       Date:  2001-09       Impact factor: 2.957

2.  Tau transgenic mice as models for cerebrospinal fluid tau biomarkers.

Authors:  Donna M Barten; Gregory W Cadelina; Nina Hoque; Lynn B DeCarr; Valerie L Guss; Ling Yang; Sethu Sankaranarayanan; Paul D Wes; Marianne E Flynn; Jere E Meredith; Michael K Ahlijanian; Charles F Albright
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Authors:  I Grundke-Iqbal; K Iqbal; Y C Tung; M Quinlan; H M Wisniewski; L I Binder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

Authors:  D Richard Lachno; Martin J Romeo; Eric R Siemers; Hugo Vanderstichele; Els Coart; Robert J Konrad; Joseph J Zajac; Jayne A Talbot; Hans F Jensen; Gopalan Sethuraman; Ronald B Demattos; Patrick C May; Robert A Dean
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

6.  Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology.

Authors:  Manuela Polydoro; Christopher M Acker; Karen Duff; Pablo E Castillo; Peter Davies
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

7.  Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments.

Authors:  T Kimura; T Ono; J Takamatsu; H Yamamoto; K Ikegami; A Kondo; M Hasegawa; Y Ihara; E Miyamoto; T Miyakawa
Journal:  Dementia       Date:  1996 Jul-Aug

Review 8.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

9.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.

Authors:  Wen-Lang Lin; Jada Lewis; Shu-Hui Yen; Michael Hutton; Dennis W Dickson
Journal:  J Neurocytol       Date:  2003-11
View more
  34 in total

1.  Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.

Authors:  Sarah L DeVos; Bianca T Corjuc; Caitlin Commins; Simon Dujardin; Riley N Bannon; Diana Corjuc; Benjamin D Moore; Rachel E Bennett; Mehdi Jorfi; Jose A Gonzales; Patrick M Dooley; Allyson D Roe; Rose Pitstick; Daniel Irimia; Matthew P Frosch; George A Carlson; Bradley T Hyman
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

2.  Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Eric H Chang; Anil K Malhotra; Peter Davies
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

3.  Methods for measuring tau pathology in transgenic mouse models.

Authors:  Stefanie K Forest; Christopher M Acker; Cristina d'Abramo; Peter Davies
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Authors:  Jeremy Koppel; Valerie Vingtdeux; Philippe Marambaud; Cristina d'Abramo; Heidy Jimenez; Mark Stauber; Rachel Friedman; Peter Davies
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

5.  DOPA Decarboxylase Modulates Tau Toxicity.

Authors:  Rebecca L Kow; Carl Sikkema; Jeanna M Wheeler; Charles W Wilkinson; Brian C Kraemer
Journal:  Biol Psychiatry       Date:  2017-06-15       Impact factor: 13.382

6.  Widespread tau seeding activity at early Braak stages.

Authors:  Jennifer L Furman; Jaime Vaquer-Alicea; Charles L White; Nigel J Cairns; Peter T Nelson; Marc I Diamond
Journal:  Acta Neuropathol       Date:  2016-11-22       Impact factor: 17.088

7.  The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.

Authors:  Daniel Paris; Ghania Ait-Ghezala; Corbin Bachmeier; Gary Laco; David Beaulieu-Abdelahad; Yong Lin; Chao Jin; Fiona Crawford; Michael Mullan
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

8.  A novel, ultrasensitive assay for tau: potential for assessing traumatic brain injury in tissues and biofluids.

Authors:  Richard Rubenstein; Binggong Chang; Peter Davies; Amy K Wagner; Claudia S Robertson; Kevin K W Wang
Journal:  J Neurotrauma       Date:  2014-12-23       Impact factor: 5.269

9.  CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Authors:  Jeremy Koppel; Valerie Vingtdeux; Philippe Marambaud; Cristina d'Abramo; Heidy Jimenez; Mark Stauber; Rachel Friedman; Peter Davies
Journal:  Mol Med       Date:  2014-03-14       Impact factor: 6.354

10.  Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities.

Authors:  Jeremy Koppel; Chris Acker; Peter Davies; Oscar L Lopez; Heidy Jimenez; Miriam Azose; Blaine S Greenwald; Patrick S Murray; Caitlin M Kirkwood; Julia Kofler; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2014-03-06       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.